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Summary Myeloma colonies (MY-CFUc) could be grown in vitro for 6 months (median time) after a group
of 12 myeloma patients had reached complete remission (CR). In a second group of 25 patients MY-CFU,
increased in 17/25 and GM-CFUc in 20/25 patients after cyclophosphamide even though 24/25 patients had a
partial response to VAMP and one was in CR. These data suggest that cell killing by cyclophosphamide
stimulates residual tumour cells into proliferation and adds further support to the idea that myeloma is under
some degree of homeostatic control which may be analogous to that in normal bone marrow. Although
lymphoplasmacytoid myeloma cells may be more drug resistant than plasmacytoid myeloma cells in vitro, it
was not possible to conclude that the emergence of lymphoplasmacytoid cells at relapse was indicative of
resistance to further treatment.
In previously untreated multiple myeloma patients the com-
plete remission rate to VAMP (vincristine, adriamycin and
methyl prednisolone) is 6% (Gore et al., 1989). This response
rate is increased to 50% (Gore et al., 1989) following further
treatment with high dose melphalan (HDM) with or without
autologous bone marrow transplantation (ABMT), compared
with 27% in patients who have received HDM as their only
treatment (Selby et al., 1987). For these purposes CR is
defined as no measurable myeloma proteins on scanning
densitometry of serum proteins separated on cellulose acetate
membrane by electrophoresis and stained with Ponceau S; no
detectable Bence Jones proteinuria on electrophoresis of neat
urine stained with colloidal gold; and less than 5% plasma
cells of normal morphology on bone marrow aspiration.
We have previously shown that two types of myeloma cell
form colonies in vitro: cells which are large and plasmacytoid
and those which are smaller and lymphoplasmacytoid (Millar
et al., 1988). Drug sensitivity tests in vitro suggest that
lymphoplasmacytoid myeloma cells are more resistant to
adriamycin than plasmacytoid myeloma cells (Millar et al.,
1989). Furthermore, the clonogenicity of myeloma cells in
vitro increases after VAMP despite a decrease in paraprotein
and reduction in bone marrow infiltration with cells of
plasma cell-like morphology (Bell et al., 1988) suggesting that
the reduction in tumour mass may stimulate quiescent cells
into cycle or induce a more malignant phenotype to become
dominant. Although multiple myeloma is characterised by
malignant plasma cells it seems likely that the stem cell of the
tumour is an earlier B cell and that major clonogenic expan-
sion occurs in committed precursor cells which have under-
gone isotype specificity. The attainment of stable plateau
phase in some patients despite measurable levels of para-
protein suggests that some degree of homeostatic regulation
is present in multiple myeloma. Furthermore, the observation
that at relapse multiple myeloma cells have more primitive
morphology in patients who become refractory to treatment
(Bartl et al., 1987) suggests that not all cells in the malignant
clone have the same sensitivity to chemotherapeutic agents
and in particular that more primitive cells may be more drug
resistant. Thus, the removal of more mature and drug sensi-
tive cells by chemotherapy may explain the emergence of
these cells at relapse and why the duration of response
tends to decrease at the second compared with first relapse
(McElwain, 1987).
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A series ofexperiments has been done to examine changes
in the clonogenicity of myeloma cells in vitro as patients
undergo treatment with VAMP and HDM. These experi-
ments have been done to determine whether in vitro data can
predict the clinical response to treatment. We have previously
shown that plasmacytoid (p) myeloma cells are more sensi-
tive to adriamycin than lymphoplasmacytoid (1) cells in vitro
and that this difference in resistance correlated with the
clinical response to VAMP (Millar et al., 1989). In view of
the greater drug resistance oflymphoplasmacytoid cells, bone
marrow samples from patients at relapse have been examined
to determine whether there is evidence for a change in
myeloma cell morphology from plasmacytoid to lympho-
plasmacytoid which may indicate resistance to further treat-
ment.
Materials and methods
Where possible patients chosen for this study had had
VAMP followed by HDM since this regimen is part of the
latest clinical trial at the Royal Marsden Hospital.
Mononuclear cells (MNC) from bone marrow aspirates of
patients with multiple myeloma were prepared and assayed
for myeloma colonies (MY-CFU,) and granulocyte-macro-
phage colonies (GM-CFU,) (Millar et al., 1989; Bradley et
al., 1978). Briefly, to culture MY-CFUc 5-10 x 105 MNC
were added as an overlay in soft agar (0.2% final concentra-
tion) and alpha modification of Eagle's medium (containing
20% fetal bovine serum, 1% bovine serum albumin, 20 lg
ml-' gentamycin sulphate) to an underlay consisting of
5 x 105 heavily irradiated HL60 cells in alpha medium and
agar (0.5% final concentration) and incubated at 37'C for
three weeks. Colonies (> 50 cells) were counted using an
inverted microscope. Melphalan sensitivity was assessed
using methods described (Millar et al., 1989). These data
were generated from survival curves for MY-CFUc and GM-
CFUC following melphalan treatment made on the same bone
marrow aspirates from each patient. Myeloma cells were
designated resistant to melphalan if the ratio of the doses of
melphalan required to reduce the surviving fraction to 10%
between MY-CFU, and GM-CFU, was 4 or greater (Millar
et al., 1989). Myeloma cells were harvested from culture after
21 days and checked that the myeloma cells were isotypic
for each patient's myeloma and for the presence of the plasma
cell marker (PCA-1; Coulter). Cells were stained with May-
Grunwald-Giemsa and examined to determine whether the
cells were plasmacytoid or lymphoplasmacytoid. Lympho-
plasmacytoid myeloma cells have approximately two-thirds
diameter of plasmacytoid myeloma cells and a greater
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nuclear:cytoplasmic volume. Within the plasmacytoid com-
partment cells have the morphology of both mature plasma
cells, blasts and immature plasma cells with well defined
nucleoli.
Myeloma cell infiltration was measured in bone marrow
aspirate smears stained with May-Grunwald-Giemsa. Serum
proteins were separated by electrophoresis (Kohn, 1976),
stained with Ponceau S, and measured by scanning densito-
metry. Paraproteins were measured as a percentage of the
total protein and expressed as gl-'.
A complete remission (CR) was defined as the absence of
measurable paraprotein and bone marrow infiltration by
myeloma cells of less than 5%. A partial response (PR) was
defined as a paraprotein level reduced by 50% and improve-
ment in all other clinical features sustained for greater than
one month. If this status was maintained the patient was said
to be in continuing partial response (CPR). Patients who
failed to fulfil any of these criteria were classified as non-
responders (NC).
Results
Table I shows the changes in clonogenic myeloma cells (MY-
CFUC) in a group of 12 patients during and after treatment
with VAMP/HDM. Four of these patients had received
chemotherapy previously (1, 3, 4, 12). The remaining eight
patients received VAMP to maximum response followed by
HDM. At the time of HDM 4/12 patients were in CR, and
eight were in PR. All 12 patients attained CR after HDM.
Melphalan sensitivity was assessed in vitro in 9/12 patients.
Four of nine patients had myeloma cells which were classed
as melphalan resistant.
The median time to clinical CR was 3-4 months (0-14
months). However, the median time for MY-CFU, to reach
zero was 8-9 months (0-15 months). In 8/12 patients
lymphoplasmacytoid as well as plasmacytoid myeloma cells
were measurable at the onset of CR. In 4/12 patients only
plasmacytoid cells formed colonies (MY-CFU,) in vitro (1, 3,
5, 7).
Since all patients receive cyclophosphamide (400 mg m-2) 7
days before HDM to enhance the recovery of normal bone
marrow progenitors (Millar et al., 1975) the number of MY-
CFUC and GM-CFUc was assessed in a group of 25 patients
immediately before cyclophosphamide and 7 days later
before they received HDM. The data in Table II show that
the number of MY-CFU, increased in 16/25 patients and
that the number ofGM-CFU, increased in 18/25 of the same
patients after cyclophosphamide. Twenty of 25 patients were
in PR and 2/25 in CR before receiving cyclophosphamide.
Table III shows the number of MY-CFU, in a group of
seven patients in first relapse after HDM. Patient 43 received
HDM alone and patient 44 received HDM + high dose
methyl prednisolone (HDMP). The median duration of re-
sponse was 9 months (6-72 months). Four patients had been
in CR after HDM and three in PR. MY-CFUc were measur-
able in 5/7 patients although all seven patients showed
growth of myeloma cells in agar/liquid culture. In 2/7
patients the morphology of the myeloma population in vitro
changed from plasmacytoid or plasmacytoid and lympho-
plasmacytoid to only lymphoplasmacytoid myeloma cells.
One patient maintained a population of plasmacytoid cells,
2/7 had both plasmacytoid and lymphoplasmacytoid during
remission and at relapse and 2/7 was not evaluable before
relapse but had both cell types subsequently. Only one
patient had GM-CFUc of less than 20 per 2 x 105 mono-
nucleated cells. This patient had plasma cell leukaemia.
Table IV shows changes in MY-CFUCin a group of eight patients at second relapse. After first relapse 7/8 patients had received VAMP followed by HDM. One patient (48) had
received VAMP followed by low dose cyclophosphamide. The median duration of second remission was 9-14 months
(0-34 months). Four of these eight patients produced MY-
CFU, and 7/8 grew in agar/liquid culture. In five patients whose myeloma cells were examined morphologically both
plasmacytoid and lymphoplasmacytoid cells were present. In
5/8 of these patients GM-CFUC was less than 20 per 2 x 105
mononucleated cells of whom 2/5 failed to produce MY-
CFUC in vitro (48, 50) and one produced only clusters of
myeloma cells (> 10 < 50 cells per cluster) (45).
Discussion
Although patients with myeloma may be operationally
defined as having achieved CR nearly all patients relapse and
only 25% respond to further conventional chemotherapy
(Bonnet et al., 1982; Kyle et al., 1982). Also, patients in CR
have measurable disease using anti-idiotypic antibodies to
detect the residual myeloma clone (Stevenson & Thompson,
1988) despite the restoration of normal haemopoiesis and
absence of detectable paraprotein. Thus, although myeloma
responds to treatment it must be thought of as a drug-
resistant tumour. The mechanism(s) of this resistance remains
to be elucidated fully; however, our data show that drug
resistance may be endogenous within the total myeloma cell
population or result from changes in the population from
cells which are drug-sensitive and resemble mature plasma
cells to more primitive drug-resistant lymphoplasmacytoid
cells (Millar et al., 1989). In 12 patients who entered CR
after VAMP/HDM, myeloma cells were measurable in vitro
for approximately 6 months after patients entered CR. Four
out of nine of their group of patients had myeloma cells that
were resistant to melphalan in our clonogenic assay. Thus in
vitro drug sensitivity per se is not a measure of whether
patients will respond to treatment. The lag period between
clinical and biological responses suggests that events other
than drug-induced toxicity are involved in achieving a stable
(non-proliferative) tumour cell population. It is arguable that
the persistence of clonogenic cells at CR is analogous to
the increase in clonogenicity reported previously after VAMP
(Bell et al., 1988) and after cyclophosphamide before patients
receive HDM (see Table II). In the original regime used
by Barlogie dexamethasone was used in place of methyl
prednisolone (VAD) and clinical remission was short in the
absence of further treatment (Barlogie et al., 1984). The
enhanced log tumour cell kill by HDM compared to VAMP
alone may reduce the number of clonogenic myeloma cells to
a level at which they eventually fail to respond to autocrine
or paracrine growth factors synthesised by the myeloma cell
population or to paracrine factors synthesised by a second
population of cells which is killed at the same time. Clearly
some degree of homeostatic control exists in this tumour and
that perturbation of the myeloma cell population (for exam-
ple, killing of non-clonogenic cells) may result in the recruit-
ment of dormant tumour cells (Bell et al., 1988).
Since MY-CFU, increased in 16/25 myeloma patients and
GM-CFUC increased in 18/25 patients after treatment with
cyclophosphamide even though 23/25 had a PR and 2/25 a CR
(to VAMP), it is arguable that similar homeostatic control
mechanisms exist in normal tissue as well as tumour. The
concept that scheduling cytotoxic drugs in specific sequences
may enhance the recovery of normal tissue has been estab-
lished for more than a decade (Millar et al., 1975; Millar &
McElwain, 1978). In animal models this phenomenon has not
been accompanied by sparing of tumour tissue (Evans et al.,
1983). However, in animal experiments the tumour models
that have been used had no capacity for differentiation or
maturation. The possibility that 'stem' cells exist in myeloma
populations raises the question of whether clonogenic mye-
loma cells that are measurable in vitro represent the stem cells
of the disease or a more differentiated population.
Our success in growing MY-CFU, from patients at relapse
was less than that from patients during treatment. In a group
of seven patients at first relapse, five yielded MY-CFU, in
vitro, one of whom (42) had received a further course of
VAMP followed by cyclophosphamide before a sample was
received. However, myeloma cells from all seven patients
grew in agar/liquid culture. Cells from two of these patients
had changed morphology; one from a mixture of plasma-MULTIPLE MYELOMA AND HOMEOSTATIC CONTROL 431
Growth of MY-CFUC and
MEL Time ofsample
sens.a after HDM
S pre(-1 wk)
4m
9m
1 m
21 m
S pre(-l wk)
3m
9m
12m
16m
R pre(-1 wk)
2m
7m
8m
S pre(-1 m)
pre(-l wk)
4m
8m
12m
R pre(-7 m)
pre(-5 m)
pre(-l wk)
lom
12m
15m
R pre(-6 m)
pre(-5 m)
pre(-l wk)
5m
11 m
n.a. pre(-6 m)
pre(-2 m)
pre(-l wk)
3m
6m
8m
n.a. pre(-1 wk)
4m
6m
9m
I m
14m
S pre(-6 m)
pre(-l m)
pre(-I wk)
9m
14m
R pre(-I wk)
7m
14m
21 m
26 m
n.a. pre(-l wk)
3m
4m
8 m
11 m
S pre(-6 m)
pre(-l wk)
6m
rm
14m
15m
GM-CFU, from patients' bone marrow before and after high dose melphalan
GM-CFU,per MY-CFUcper
2 x 105 MNC 106 MNC Responseb Cell typec Treatmentd
134 40 PR p
25
18
18
36
60
10
2
10
20
68
S
8
4
114
61
35
25
14
75
17
131
5
41
32
83
39
94
13
0
44
112
84
6
17
3
19
0
4
4
18
39
74
42
88
55
16
86
15
0
4
3
23
26
14
30
2
3
120
18
50
34
70
31
0
0/+ +
0
40
5
16
2
0
22
0/ +
0
0
21
26
13
0
10
5
6
9
4
0/ +
10
85
117
6
0
11
500
5
16
0/ +
I
10
3
0
1
4
0
15
2
116
0/ +
0
130
14
0
1
1
34
0/ +
0/ +
0/ +
0/ +
7
na.
12
19
3
21
CR
CR
CR
CR
PR
CR
CR
CR
CR
CR
CCR
PD
NC
n.a.
PR
CR
CR
PD
CR
CCR
CCR
CCR
CCR
CR
CCR
CCR
CCR
PR
CPR
CR
CCR
CCR
PR
CPR
CPR
CPR
CR
CR
PR
PR
CR
CR
PR
PR
CR
CR
CR
CR
CCR
CCR
CCR
CCR
Relapse
PR
CR
PD
PD
PD
p
n.a.
I
n.a.
p& I
p& I
p& I
n.a.
n.a.
p
p
n.a.
n.a.
p
p
p&l
n.a.
p&1
p
p
p& 1
p& 1
p
p
p&l
p&l
p&l
p&1
n.a.
p&l
p&l
p&1
p
p
p&
p& 1
p& 1
n.a.
p&l
p&l
n.a.
p
p&l
n.a.
p&l
p&1 p& 1
p& 1
p&
p&
p&1
p
n.a.
p&l
p&l
p&l
n&1
Elsewhere
VAMP x 6
HDM + ABMT
NFT
NFT
NFT
VAMP x 5
HDM + ABMT
NFT
NFT
NFT
HDM + HDMP
CY-VAMP x 4
HDM + ABMT
NFT
CY-VAMP x 3
CHOP + MTX
+ LDM
NFT
HDM + ABMT
NFT
NFT
NT
VAMP x 4
VER-VAMP x 3
HDM + ABMT
NFT
NFT
NT
VAMP x I
VAMP x 5
HDM + ABMT
NFT
NT
VAMP x 4
VAMP x 2
HDM + ABMT
NFT
NFT
VAMP x 6
HDM + ABMT
NFT
NFT
NFT
NFT
NT
VAMP x 7
NFT
HDM + ABMT
NFT
VAMP x 6
HDM + ABMT
NFT
NFT
NFT
VAMP x 5
HDM + ABMT
NFT
NFT
NFT
VAD x 3
HDM + HDMP
CY-VAMP x 3
VER-VAMP x 2
HDM + ABMT
NFT
NFT
NFT
aMelphalan sensitivity (R = resistant; S = sensitive). bn.a., not available; CR, complete remission; CCR, continued
complete remission; PR, partial response; CPR, continued partial response; PD, progressive disease; NC, no change.
Cp = plasmacytoid; 1 = lymphoplasmacytoid. dVAMP, vincristine (0.4mg daily, days 1 -4); adriamycin 9 mg m2 daily, days
1-4); methyl prednisolone (1 g m2 daily, days 1-5). HDM + HDMP, high dose melphalan (140mg m2) + methyl
prednisolone (1 g m-2 daily for 5 days). HDM + ABMT, high dose melphalan (200 mg m-2) + autologous bone marrow
transplantation. CY-VAMP, VAMP plus 500 mg cyclophosphamide (days 1, 8 and 15). VER-VAMP, VAMP plus verapamil
(10 mg i.v. over 24 h, days 1 -5). CHOP, cyclophosphamide (750 mg m-2 i.,v. day 1); adriamycin (50 mg m 2 i.v. day 1);
vincristine (1.4 mg m-2 (max. 2 mg) day 1); methyl prednisolone (100 mg m-2, orally days 1 -5). MTX, methotrexate, dose
unknown, treated elsewhere. LDM, low dose melphalan. NT, no treatment. NFT, no further treatment. e 0/ + growth as
colonies or clusters in liquid overlay only; no growth in soft agar overlay.
Table I
Patient
I
2
3
4
5
6
7
8
9
10
11
12432 J.A. MAITLAND et al.
Table II Growth of MY-CFU, and GM-CFU, from patients' bone marrow
before and after cyclophosphamide (CY)
Patient
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Response before
receiving CY
PR
PR
PR
PR
PR
PR
PR (NC)
PR
PR
PR
CR
PR
PR
PR
PR
PR
PR
PR
PR
PR
CR
PR
PR
PR
PR
acl = clusters (< 50 cells).
GM-CFUcper
2 x 106 MNC
Pre CY Post CY
30 46
33 42
72 n.a.
42 88
30 92
52 171
6 80
15 28
61 26
n.a. 66
23 n.a.
13 16
114 61
2 72
n.a. 85
59 159
9 133
13 98
79 131
1 23
39 94
41 45
84 167
4 27
63 3
MY-CFUcper
106 MNC
Pre CY Post CY
cla 65
1 1
O+cl 76
2 116
0 13cl
0 30
4 3cl
n.a. 3
20 11
0+cl 70
34 n.a.
O+cl 200
21 26
4 39cl
Icl 19
6 4
0 58
0 35cl
11 6
0 30
85 117
30 35
S n.a.
0 0
1 + 3cl 7
Table III Growth of MY-CFU, and GM-CFU, from patients' bone marrow in first relapse after VAMP/HDM
Cell type
Response Duration of Time ofsample GM-CFU,L per MY-CFU, per presentation
Patient after HDM clinical response after HDM 2 x 105 MNC 106 MNC to relapse
38 PR 6 m 12 m 25 52 p to p (blasts)
39 CR 9m 9m 40 O/+b pl topl
40 PR loim lom 3 0/ + pl to I
41 CR 9m 9 m 55 7 pl topl
42 PR 6m lOm 31 39 p to I
433 CR 72m 72m 62 52 n.a. to pl
44 CR 20m 20m 25 32 n.a. to pl
aNo VAMP. bGrowth in agar/liquid culture only.
Table IV Growth of MY-CFUC and GM-CFUC from patients' bone marrow at or after second relapse
Treatment Response and 2nd response Duration Time of
to 1st duration of after of2nd sample after GM-CFU, per MY-CFU, per Cell type
Patient relapsea 1st response VAMP/HDM response 2nd response 2 x 105 MNC 106 MNC at relapse
3 HDM + HDMP CR 21 m CR 29 m 17 m 68 22 n.a.
7 VAD x 2 CR 23m CR 9m 13m 18 12 p& I
HDM + HDMP
45 VAD x 3 CR 21 m PR 4m 3.5 m 8 Scls n.a.
HDM + HDMP
46 ABCM NC - CR 19 m 25 m 36 0 n.a.
47 HDM CR 26m CR 14m 46m 8 5 p &l
48 Unknown n.a. PR 5 m 5 m 4 0/ + p & 1
49 Elsewhere n.a. CR 34 m 33 m 35 32 p & 1
50 LDM NC/PD - PR 6m I m 12 0/ + p &
MP x 3
aVAD, vincristine, adriamycin; HDM, high dose melphalan; HDMP, high dose methylprednisolone; ABCM, adriamycin, BCNU, melphalan,
cyclophosphamide; LDM, low dose melphalan; MP, methylprednisolone.
cytoid and lymphoplasmacytoid to lymphoplasmacytoid (40)
and a second from plasmacytoid to lymphoplasmacytoid
(42). At second relapse cells from 4/8 patients produced
MY-CFU, in vitro. In this group, five patients yielded less
than 20 GM-CFU, per 2 x 105 mononucleated cells. The
reduced number of GM-CFU, from patients at second re-
lapse may reflect damage to the bone marrow as a result of
chemotherapy and/or failure of normal precursor cells to
respond to endogenous lymphokines and produce mature
elements. In three of this group of patients who have further
treatment (45, 48, 49), the number of GM-CFU, increased
again after VAMP and the number of MY-CFU, increased
in two.
Since both plasmacytoid and lymphoplasmacytoid myeloma
cells formed MY-CFU, in vitro from patients at first and
second relapse, we cannot claim to predict the future res-
ponse at second relapse of these patients to chemotherapy
based on the emergence of lymphoplasmacytoid cells.
The present report emphasises that the growth of myeloma
cells in vitro is dependent on the treatment that patients
receive. Chemotherapy with VAMP and/or cyclophospha-
mide reproducibly increases the number ofMY-CFU, in vitroMULTIPLE MYELOMA AND HOMEOSTATIC CONTROL 433
even though patients have responded to treatment. This sug-
gests that at presentation or relapse, when bone marrow
infiltration may be high, a large proportion of the myeloma
cell population are end cells or that colony growth in vitro
is inhibited due to the high density of malignant cells,
analogous to the inhibition of growth of cell lines in vitro
when cells are seeded at concentrations approaching satura-
tion density. Our method successfully mimicked the clinical
response of patients who exhibited CR after VAMP/HDM
although the mechanism of the clinical response cannot be
explained entirely by the in vitro sensitivity of myeloma cells
to melphalan.
We thank the Cancer Research Campaign, the Medical Research
Council and the Leukaemia Research Fund for support, and the
theatre staff and nurses of the IBM Unit at the Royal Marsden
Hospital for their co-operation.
References
BARLOGIE, B., SMITH, L. & ALEXANIAN, R. (1984). Effective treat-
ment of advanced multiple myeloma refractory to alkylating
agents. N. Engi. J. Med., 310, 1353.
BARTL, R., FRISCH, B., FATEH-MOGHADAM, A., KETTNER, G.,
JAEGER, K. & SOMMERFELD, W. (1987). Histologic classification
and staging of multiple myeloma. A retrospective and prospective
study of 674 cases. Am. J. Clin. Pathol., 87, 342.
BELL, J.B.G., MILLAR, B.C., MAITLAND, J.A., NANDI, A., GORE, M.
& MCELWAIN, T.J. (1988). Increase in clonogenic tumour cells in
bone marrow of patients with multiple myeloma treated with
vincristine, doxorubicin and methylprednisolone. Lancet, ii, 931.
BONNET, J., ALEXANIAN, R., SALMON, S. & 4 others (1982). Vincris-
tine, BCNU, doxorubicin and prednisolone (VBAP) combination
in the treatment of relapsing or resistant myeloma: a Southwest
Oncology Group study. Cancer Treat. Rep., 66, 1267.
BRADLEY, T.R., HODGSON, G.S. & ROSENDAAL, M. (1978). The
effect of oxygen tension on haemopoietic and fibroblast cell
proliferation in vitro. J. Cell. Physiol., 97, 517.
EVANS, B.D., SMITH, I.E., CLUTTERBUCK, R.D. & MILLAR, J.L.
(1983). Normal tissue toxicity and antitumour experiments car-
ried out in mice using high-dose cyclophosphamide. Cancer
Treat. Rev., 10, 25.
GORE, M.E., SELBY, P.J., VINER, C. & 12 others (1989). Intensive
treatment of multiple myeloma and critera for complete remis-
sion. Lancet, ii, 879.
KOHN, J. (1976). Cellulose acetate electrophoresis and
immunodiffusion techniques. In Chromatographic and Electro-
phorectic Techniques, Vol. 2, Smith, I. (ed.) p. 90. Heinemann:
London.
KYLE, R.A., PAJAK, T.F., HENDERSON, E.S. & 5 others (1982). Mul-
tiple myeloma resistant to melphalan: treatment with doxo-
rubicin, cyclophosphamide, carmustine (BCNU) and prednisone.
Cancer Treat. Rep., 66, 451.
McELWAIN, T.J. (1987). The modern management of myeloma. In
Advanced Medicine, Vol. 23, Pounder, R.E. & Chiodini, P.L.
(eds) p. 215. Baillere Tindall: London.
MILLAR, B.C., BELL, J.B.G., LAKHANI, A., AYLIFFE, M.J., SELBY,
P.J. & MCELWAIN, T.J. (1988). A simple method for culturing
myeloma cells from human bone marrow aspirates and peripheral
blood in vitro. Br. J. Haematol., 69, 197.
MILLAR, B.C., BELL, J.B.G., MAITLAND, J.A. & 4 others (1989). In
vitro studies of ways to overcome resistance to VAMP-high dose
melphalan in the treatment of multiple myeloma. Br. J.
Haematol., 71, 213.
MILLAR, J.L., HUDSPITH, B.N. & BLACKETT, N.M. (1975). Reduced
lethality in mice receiving a combined dose of cyclophosphamide
and busulphan. Br. J. Cancer, 32, 193.
MILLAR, J.L. & McELWAIN, T.J. (1978). Combinations of cytotoxic
agents that have less than expected toxicity on normal tissues in
mice. In Fundamentals in Cancer Chemotherapy, Antibiotics and
Chemotherapy, Schonfeld, H. (ed.) p. 271. Karger: Basel.
SELBY, P.J., MCELWAIN, T.J., NANDI, A.C. & 6 others (1987). Mul-
tiple myeloma treated with high dose intravenous melphalan. Br.
J. Haematol., 66, 55.
STEVENSON, G.T. & THOMPSON, J. (1988). Idiotypes and anti-
idiotypes in myeloma. Hematol. Oncol., 6, 103.